Celltrion Launches Two Oncology Drugs in Vietnam, Expanding Sales Portfolio to Four Products
Accelerating Prescriptions Through Marketing Synergy Between Products
Maintaining Top Market Share for Key Product Lines in Major Asian Countries
Maximizing Performance Growth With the Launch of High-Profit Follow-Up Products
Celltrion announced on June 15 that it launched the blood cancer treatment 'Truxima' (ingredient name: Rituximab) and the metastatic colorectal and breast cancer treatment 'Vegzelma' (ingredient name: Bevacizumab) in Vietnam, a key ASEAN country, on June 9 (local time).
The company aims to drive performance growth by expanding its product portfolio in Pharmerging markets such as Asia and Latin America. Both products were supplied to the market approximately three months after receiving sales approval in March this year, achieving early market entry.
Following last year's launch of the autoimmune disease treatment 'Remsima' (ingredient name: Infliximab) and the breast and gastric cancer treatment 'Herzuma' (ingredient name: Trastuzumab) in Vietnam, Celltrion has now expanded its sales portfolio to four products by adding these two oncology drugs. With this expanded portfolio, the company plans to accelerate prescriptions by leveraging marketing synergies between its products.
Celltrion's Vietnamese subsidiary plans to focus on securing the supply chain for the new products by utilizing the hospital network and bidding experience gained from selling Herzuma, which is also an oncology drug. Since the launch of Herzuma, the Vietnamese subsidiary has proven its direct sales capabilities by winning 25 out of 48 Trastuzumab tenders held at major local hospitals.
Outside Vietnam, Celltrion's sales performance is also notable in other major Asian countries. According to pharmaceutical market research firm IQVIA, Celltrion's flagship product Remsima leads the market in Singapore with a 96% share, and maintains the top market share in Thailand (77%) and Malaysia (59%).
Remsima's success extends to the world’s only infliximab subcutaneous injection treatment, 'RemsimaSC.' In Hong Kong, RemsimaSC is rapidly growing with a 29% market share, and the combined share of Remsima-related products has reached 82%, establishing Celltrion as the leading provider of autoimmune disease treatments in the Hong Kong infliximab market.
Celltrion is also strengthening its dominance in the oncology segment. Herzuma leads the Thai market with an 82% share and holds the number one position in Hong Kong (64%) and Malaysia (53%) as well. Truxima also ranks first in prescriptions in Singapore (81%) and Thailand (74%).
Sales momentum continues in Latin America. In Costa Rica, both Remsima and Truxima have secured nearly 100% market share, while in Ecuador, Truxima holds around 80%, and in the Dominican Republic and Paraguay, Remsima commands approximately 80% market share in each country.
Celltrion plans to further strengthen its commercial competitiveness in Pharmerging markets through continued portfolio expansion and successful bidding efforts. In Vietnam, the company is preparing to launch subsequent products such as RemsimaSC, while in Indonesia, where a subsidiary was established last year, Celltrion aims to expand its market influence with the launch of major product lines. In Latin America, the company intends to broaden its impact by releasing follow-up products such as Omlyclo and increasing participation in public institution tenders.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Celltrion spokesperson stated, “The launch of new oncology drugs has enabled us to pursue a much more aggressive sales strategy in Vietnam,” adding, “Starting this year, we will maximize performance growth by gradually expanding the launch of high-profit follow-up products, focusing on Pharmerging markets.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.